Fig. 2

The prognosis of HTLV-1-positive patients. Patients administered Ooitabi (Ficus pumila L.) (solid line) had a significantly better prognosis than those who were not (dashed line). A crossing of the Progression Free Survival curves was noted, representing a delay in benefit with inhibitors that may be typical with immunotherapy, but survival improves and eventually Tail plateaus over time. A similar prognosis was observed with immune checkpoint inhibitors. Ficus pumila L. may restore the original function of T cells and suppress tumor activation. The HTLV-1 antibody was measured by the gelatin particle agglutination method (BML, Inc., Japan). When measuring Progression Free Survival, follow-up data that were reached as of the last follow-up date or at 1500 days after treatment onset were used. Patient prognoses were analyzed using the Kaplan Meier method and the log rank test was used to determine the univariate significance of the variables. P < 0.05 was considered to indicate statistical significance